AACR: Ger­many's small NK cell play­er Af­fimed makes a big splash with ear­ly lym­phoma da­ta

Ger­man small-cap Af­fimed has long been high­light­ed as a po­ten­tial Cin­derel­la sto­ry, win­ning mile­stone-rich deals with Genen­tech and Roivant. And on Fri­day the biotech con­tin­ued its NK cell march, pre­sent­ing the first look at in-hu­man da­ta ahead of this week­end’s AACR con­fer­ence.

Re­searchers saw sig­nif­i­cant dis­ease re­duc­tion in all four lym­phoma pa­tients dosed with Af­fimed’s ex­per­i­men­tal off-the-shelf NK cell ther­a­py, with two reg­is­ter­ing com­plete re­spons­es as of the March 31 da­ta cut­off, the com­pa­ny an­nounced. All of the pa­tients had been heav­i­ly pre­treat­ed — with a range of four to 14 lines of pri­or ther­a­py — and there were no signs of cy­tokine re­lease syn­drome, tox­i­c­i­ty or graft-ver­sus-host dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER